Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second MenC conjugate booster age study in previously primed Dutch children
NL-OMON26279Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal group C disease, sponsored by National Institute for Public Health and the Environment. Primary endpoint: Serum bactericidal antibody persistence. Started Oct 2011; status: active, not recruiting.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal group C disease
Beyond the preview
Go deeper on NL-OMON26279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26279.